Research programme: dendritic cell monoclonal antibodies - Alexion/UMC Nijmegen

Drug Profile

Research programme: dendritic cell monoclonal antibodies - Alexion/UMC Nijmegen

Alternative Names: Anti-DC-SIGN antibodies; Anti-L-SIGN antibodies; Cancer vaccine - Alexion/UMC Nijmegen

Latest Information Update: 16 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University Medical Centre of Nijmegen
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Jan 2007 Preclinical development is ongoing for Cancer
  • 29 Sep 2005 This programme is still in active development
  • 18 Nov 2003 Preclinical trials in Cancer in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top